DexCom, Inc.
DexCom, Inc. DXCM Peers
See (DXCM) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| DXCM | $79.83 | -0.21% | 31.3B | 60.02 | $1.33 | N/A |
| ABT | $133.26 | +0.20% | 231.9B | 17.28 | $7.71 | +1.72% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| BSX | $102.36 | +1.05% | 151.4B | 73.64 | $1.39 | N/A |
| SYK | $379.16 | +0.96% | 144.9B | 51.24 | $7.40 | +0.88% |
| MDT | $85.98 | -0.42% | 110.3B | 23.82 | $3.61 | +3.25% |
| EW | $75.30 | +1.99% | 44.2B | 31.12 | $2.42 | N/A |
| STE | $236.91 | +0.53% | 23.3B | 38.40 | $6.17 | +0.97% |
| PODD | $307.67 | +1.49% | 21.7B | 55.44 | $5.55 | N/A |
| PHG | $22.67 | +1.70% | 21B | 75.57 | $0.30 | +3.97% |
Stock Comparison
DXCM vs ABT Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, ABT has a market cap of 231.9B. Regarding current trading prices, DXCM is priced at $79.83, while ABT trades at $133.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas ABT's P/E ratio is 17.28. In terms of profitability, DXCM's ROE is +0.24%, compared to ABT's ROE of +0.31%. Regarding short-term risk, DXCM is more volatile compared to ABT. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.
DXCM vs BSX-PA Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, DXCM is priced at $79.83, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, DXCM's ROE is +0.24%, compared to BSX-PA's ROE of +0.10%. Regarding short-term risk, DXCM is more volatile compared to BSX-PA. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.
DXCM vs BSX Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, BSX has a market cap of 151.4B. Regarding current trading prices, DXCM is priced at $79.83, while BSX trades at $102.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas BSX's P/E ratio is 73.64. In terms of profitability, DXCM's ROE is +0.24%, compared to BSX's ROE of +0.10%. Regarding short-term risk, DXCM is more volatile compared to BSX. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.
DXCM vs SYK Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, SYK has a market cap of 144.9B. Regarding current trading prices, DXCM is priced at $79.83, while SYK trades at $379.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas SYK's P/E ratio is 51.24. In terms of profitability, DXCM's ROE is +0.24%, compared to SYK's ROE of +0.11%. Regarding short-term risk, DXCM is more volatile compared to SYK. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.
DXCM vs MDT Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, MDT has a market cap of 110.3B. Regarding current trading prices, DXCM is priced at $79.83, while MDT trades at $85.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas MDT's P/E ratio is 23.82. In terms of profitability, DXCM's ROE is +0.24%, compared to MDT's ROE of +0.10%. Regarding short-term risk, DXCM is more volatile compared to MDT. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.
DXCM vs EW Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, EW has a market cap of 44.2B. Regarding current trading prices, DXCM is priced at $79.83, while EW trades at $75.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas EW's P/E ratio is 31.12. In terms of profitability, DXCM's ROE is +0.24%, compared to EW's ROE of +0.49%. Regarding short-term risk, DXCM is more volatile compared to EW. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.
DXCM vs STE Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, STE has a market cap of 23.3B. Regarding current trading prices, DXCM is priced at $79.83, while STE trades at $236.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas STE's P/E ratio is 38.40. In terms of profitability, DXCM's ROE is +0.24%, compared to STE's ROE of +0.09%. Regarding short-term risk, DXCM is more volatile compared to STE. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.
DXCM vs PODD Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, PODD has a market cap of 21.7B. Regarding current trading prices, DXCM is priced at $79.83, while PODD trades at $307.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas PODD's P/E ratio is 55.44. In terms of profitability, DXCM's ROE is +0.24%, compared to PODD's ROE of +0.35%. Regarding short-term risk, DXCM is more volatile compared to PODD. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.
DXCM vs PHG Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, PHG has a market cap of 21B. Regarding current trading prices, DXCM is priced at $79.83, while PHG trades at $22.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas PHG's P/E ratio is 75.57. In terms of profitability, DXCM's ROE is +0.24%, compared to PHG's ROE of +0.03%. Regarding short-term risk, DXCM is more volatile compared to PHG. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.
DXCM vs ZBH Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, ZBH has a market cap of 18.1B. Regarding current trading prices, DXCM is priced at $79.83, while ZBH trades at $91.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas ZBH's P/E ratio is 20.33. In terms of profitability, DXCM's ROE is +0.24%, compared to ZBH's ROE of +0.07%. Regarding short-term risk, DXCM is more volatile compared to ZBH. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.
DXCM vs ABMD Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, DXCM is priced at $79.83, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas ABMD's P/E ratio is 65.36. In terms of profitability, DXCM's ROE is +0.24%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, DXCM is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.
DXCM vs ALGN Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, ALGN has a market cap of 13.3B. Regarding current trading prices, DXCM is priced at $79.83, while ALGN trades at $183.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas ALGN's P/E ratio is 33.29. In terms of profitability, DXCM's ROE is +0.24%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, DXCM is less volatile compared to ALGN. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.
DXCM vs SNN Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, SNN has a market cap of 12.8B. Regarding current trading prices, DXCM is priced at $79.83, while SNN trades at $29.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas SNN's P/E ratio is 31.02. In terms of profitability, DXCM's ROE is +0.24%, compared to SNN's ROE of +0.08%. Regarding short-term risk, DXCM is more volatile compared to SNN. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.
DXCM vs SWAV Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, DXCM is priced at $79.83, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas SWAV's P/E ratio is 78.76. In terms of profitability, DXCM's ROE is +0.24%, compared to SWAV's ROE of +0.14%. Regarding short-term risk, DXCM is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.
DXCM vs PEN Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, PEN has a market cap of 9.9B. Regarding current trading prices, DXCM is priced at $79.83, while PEN trades at $254.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas PEN's P/E ratio is 235.68. In terms of profitability, DXCM's ROE is +0.24%, compared to PEN's ROE of +0.04%. Regarding short-term risk, DXCM is less volatile compared to PEN. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.
DXCM vs GMED Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, GMED has a market cap of 7.8B. Regarding current trading prices, DXCM is priced at $79.83, while GMED trades at $57.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas GMED's P/E ratio is 43.15. In terms of profitability, DXCM's ROE is +0.24%, compared to GMED's ROE of +0.05%. Regarding short-term risk, DXCM is more volatile compared to GMED. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.
DXCM vs BIO-B Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, BIO-B has a market cap of 6.8B. Regarding current trading prices, DXCM is priced at $79.83, while BIO-B trades at $250.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas BIO-B's P/E ratio is -3.27. In terms of profitability, DXCM's ROE is +0.24%, compared to BIO-B's ROE of -0.32%. Regarding short-term risk, DXCM is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.
DXCM vs BIO Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, BIO has a market cap of 6.4B. Regarding current trading prices, DXCM is priced at $79.83, while BIO trades at $235.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas BIO's P/E ratio is -3.08. In terms of profitability, DXCM's ROE is +0.24%, compared to BIO's ROE of -0.32%. Regarding short-term risk, DXCM is less volatile compared to BIO. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.
DXCM vs BRKR Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, BRKR has a market cap of 5.9B. Regarding current trading prices, DXCM is priced at $79.83, while BRKR trades at $38.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas BRKR's P/E ratio is 74.48. In terms of profitability, DXCM's ROE is +0.24%, compared to BRKR's ROE of +0.04%. Regarding short-term risk, DXCM is less volatile compared to BRKR. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.
DXCM vs GKOS Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, GKOS has a market cap of 5.5B. Regarding current trading prices, DXCM is priced at $79.83, while GKOS trades at $96.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas GKOS's P/E ratio is -42.65. In terms of profitability, DXCM's ROE is +0.24%, compared to GKOS's ROE of -0.17%. Regarding short-term risk, DXCM is less volatile compared to GKOS. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.
DXCM vs IRTC Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, IRTC has a market cap of 4.8B. Regarding current trading prices, DXCM is priced at $79.83, while IRTC trades at $151.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas IRTC's P/E ratio is -48.09. In terms of profitability, DXCM's ROE is +0.24%, compared to IRTC's ROE of -1.13%. Regarding short-term risk, DXCM is less volatile compared to IRTC. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.
DXCM vs NARI Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, DXCM is priced at $79.83, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas NARI's P/E ratio is -59.24. In terms of profitability, DXCM's ROE is +0.24%, compared to NARI's ROE of -0.18%. Regarding short-term risk, DXCM is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.
DXCM vs TMDX Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, TMDX has a market cap of 4.3B. Regarding current trading prices, DXCM is priced at $79.83, while TMDX trades at $127.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas TMDX's P/E ratio is 90.45. In terms of profitability, DXCM's ROE is +0.24%, compared to TMDX's ROE of +0.22%. Regarding short-term risk, DXCM is less volatile compared to TMDX. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.
DXCM vs ITGR Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, ITGR has a market cap of 4.2B. Regarding current trading prices, DXCM is priced at $79.83, while ITGR trades at $119.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas ITGR's P/E ratio is 55.41. In terms of profitability, DXCM's ROE is +0.24%, compared to ITGR's ROE of +0.05%. Regarding short-term risk, DXCM is more volatile compared to ITGR. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.
DXCM vs INSP Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, INSP has a market cap of 3.8B. Regarding current trading prices, DXCM is priced at $79.83, while INSP trades at $130.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas INSP's P/E ratio is 59.39. In terms of profitability, DXCM's ROE is +0.24%, compared to INSP's ROE of +0.10%. Regarding short-term risk, DXCM is less volatile compared to INSP. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.
DXCM vs AXNX Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, DXCM is priced at $79.83, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas AXNX's P/E ratio is -709.80. In terms of profitability, DXCM's ROE is +0.24%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, DXCM is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.
DXCM vs PRCT Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, PRCT has a market cap of 3.2B. Regarding current trading prices, DXCM is priced at $79.83, while PRCT trades at $58.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas PRCT's P/E ratio is -34.75. In terms of profitability, DXCM's ROE is +0.24%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, DXCM is more volatile compared to PRCT. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.
DXCM vs LIVN Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, LIVN has a market cap of 2.5B. Regarding current trading prices, DXCM is priced at $79.83, while LIVN trades at $45.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas LIVN's P/E ratio is -11.20. In terms of profitability, DXCM's ROE is +0.24%, compared to LIVN's ROE of -0.18%. Regarding short-term risk, DXCM is more volatile compared to LIVN. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.
DXCM vs NUVA Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, DXCM is priced at $79.83, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas NUVA's P/E ratio is 75.00. In terms of profitability, DXCM's ROE is +0.24%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, DXCM is less volatile compared to NUVA. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.
DXCM vs UFPT Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, UFPT has a market cap of 1.8B. Regarding current trading prices, DXCM is priced at $79.83, while UFPT trades at $233.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas UFPT's P/E ratio is 28.61. In terms of profitability, DXCM's ROE is +0.24%, compared to UFPT's ROE of +0.19%. Regarding short-term risk, DXCM is more volatile compared to UFPT. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.
DXCM vs CNMD Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, CNMD has a market cap of 1.6B. Regarding current trading prices, DXCM is priced at $79.83, while CNMD trades at $51.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas CNMD's P/E ratio is 13.56. In terms of profitability, DXCM's ROE is +0.24%, compared to CNMD's ROE of +0.13%. Regarding short-term risk, DXCM is less volatile compared to CNMD. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.
DXCM vs ATEC Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, ATEC has a market cap of 1.6B. Regarding current trading prices, DXCM is priced at $79.83, while ATEC trades at $10.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas ATEC's P/E ratio is -9.54. In terms of profitability, DXCM's ROE is +0.24%, compared to ATEC's ROE of -2.58%. Regarding short-term risk, DXCM is less volatile compared to ATEC. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.
DXCM vs TNDM Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, TNDM has a market cap of 1.3B. Regarding current trading prices, DXCM is priced at $79.83, while TNDM trades at $20.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas TNDM's P/E ratio is -7.25. In terms of profitability, DXCM's ROE is +0.24%, compared to TNDM's ROE of -0.83%. Regarding short-term risk, DXCM is less volatile compared to TNDM. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.
DXCM vs AORT Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, AORT has a market cap of 1.3B. Regarding current trading prices, DXCM is priced at $79.83, while AORT trades at $30.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas AORT's P/E ratio is -60.51. In terms of profitability, DXCM's ROE is +0.24%, compared to AORT's ROE of -0.07%. Regarding short-term risk, DXCM is less volatile compared to AORT. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.
DXCM vs HSKA Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, DXCM is priced at $79.83, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas HSKA's P/E ratio is -62.49. In terms of profitability, DXCM's ROE is +0.24%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, DXCM is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.
DXCM vs AHCO Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, AHCO has a market cap of 1.1B. Regarding current trading prices, DXCM is priced at $79.83, while AHCO trades at $8.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas AHCO's P/E ratio is 14.34. In terms of profitability, DXCM's ROE is +0.24%, compared to AHCO's ROE of +0.06%. Regarding short-term risk, DXCM is less volatile compared to AHCO. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.
DXCM vs SILK Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, DXCM is priced at $79.83, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas SILK's P/E ratio is -18.96. In terms of profitability, DXCM's ROE is +0.24%, compared to SILK's ROE of -0.29%. Regarding short-term risk, DXCM is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.
DXCM vs FNA Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, DXCM is priced at $79.83, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas FNA's P/E ratio is -19.83. In terms of profitability, DXCM's ROE is +0.24%, compared to FNA's ROE of -0.36%. Regarding short-term risk, DXCM is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.
DXCM vs SSII Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, SSII has a market cap of 1.1B. Regarding current trading prices, DXCM is priced at $79.83, while SSII trades at $5.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas SSII's P/E ratio is -70.62. In terms of profitability, DXCM's ROE is +0.24%, compared to SSII's ROE of -1.33%. Regarding short-term risk, DXCM is less volatile compared to SSII. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.
DXCM vs ESTA Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, ESTA has a market cap of 1.1B. Regarding current trading prices, DXCM is priced at $79.83, while ESTA trades at $36.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas ESTA's P/E ratio is -11.72. In terms of profitability, DXCM's ROE is +0.24%, compared to ESTA's ROE of -2.10%. Regarding short-term risk, DXCM is less volatile compared to ESTA. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.
DXCM vs INMD Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, INMD has a market cap of 938.3M. Regarding current trading prices, DXCM is priced at $79.83, while INMD trades at $13.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas INMD's P/E ratio is 6.05. In terms of profitability, DXCM's ROE is +0.24%, compared to INMD's ROE of +0.25%. Regarding short-term risk, DXCM is less volatile compared to INMD. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.
DXCM vs IART Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, IART has a market cap of 903.8M. Regarding current trading prices, DXCM is priced at $79.83, while IART trades at $11.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas IART's P/E ratio is -30.61. In terms of profitability, DXCM's ROE is +0.24%, compared to IART's ROE of -0.03%. Regarding short-term risk, DXCM is less volatile compared to IART. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.
DXCM vs CSII Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, DXCM is priced at $79.83, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas CSII's P/E ratio is -20.83. In terms of profitability, DXCM's ROE is +0.24%, compared to CSII's ROE of -0.14%. Regarding short-term risk, DXCM is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.
DXCM vs IRMD Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, IRMD has a market cap of 757.7M. Regarding current trading prices, DXCM is priced at $79.83, while IRMD trades at $59.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas IRMD's P/E ratio is 38.45. In terms of profitability, DXCM's ROE is +0.24%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, DXCM is more volatile compared to IRMD. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.
DXCM vs CRY Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, DXCM is priced at $79.83, while CRY trades at $17.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas CRY's P/E ratio is 425.71. In terms of profitability, DXCM's ROE is +0.24%, compared to CRY's ROE of -0.07%. Regarding short-term risk, DXCM is less volatile compared to CRY. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.
DXCM vs SIBN Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, SIBN has a market cap of 704M. Regarding current trading prices, DXCM is priced at $79.83, while SIBN trades at $16.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas SIBN's P/E ratio is -26.22. In terms of profitability, DXCM's ROE is +0.24%, compared to SIBN's ROE of -0.16%. Regarding short-term risk, DXCM is less volatile compared to SIBN. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.
DXCM vs CBLL Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, CBLL has a market cap of 668.3M. Regarding current trading prices, DXCM is priced at $79.83, while CBLL trades at $18.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas CBLL's P/E ratio is -14.79. In terms of profitability, DXCM's ROE is +0.24%, compared to CBLL's ROE of -1.64%. Regarding short-term risk, DXCM is less volatile compared to CBLL. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.
DXCM vs APEN Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, DXCM is priced at $79.83, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas APEN's P/E ratio is -9.43. In terms of profitability, DXCM's ROE is +0.24%, compared to APEN's ROE of -0.85%. Regarding short-term risk, DXCM is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.
DXCM vs AVNS Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, AVNS has a market cap of 560.5M. Regarding current trading prices, DXCM is priced at $79.83, while AVNS trades at $12.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas AVNS's P/E ratio is -1.47. In terms of profitability, DXCM's ROE is +0.24%, compared to AVNS's ROE of -0.37%. Regarding short-term risk, DXCM is more volatile compared to AVNS. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.
DXCM vs RXST Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, RXST has a market cap of 549.8M. Regarding current trading prices, DXCM is priced at $79.83, while RXST trades at $13.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas RXST's P/E ratio is -20.50. In terms of profitability, DXCM's ROE is +0.24%, compared to RXST's ROE of -0.10%. Regarding short-term risk, DXCM is less volatile compared to RXST. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.
DXCM vs KIDS Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, KIDS has a market cap of 510M. Regarding current trading prices, DXCM is priced at $79.83, while KIDS trades at $20.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas KIDS's P/E ratio is -11.70. In terms of profitability, DXCM's ROE is +0.24%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, DXCM is less volatile compared to KIDS. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.
DXCM vs BFLY Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, BFLY has a market cap of 505.7M. Regarding current trading prices, DXCM is priced at $79.83, while BFLY trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas BFLY's P/E ratio is -6.82. In terms of profitability, DXCM's ROE is +0.24%, compared to BFLY's ROE of -0.33%. Regarding short-term risk, DXCM is less volatile compared to BFLY. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.
DXCM vs SMLR Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, SMLR has a market cap of 468.2M. Regarding current trading prices, DXCM is priced at $79.83, while SMLR trades at $41.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas SMLR's P/E ratio is -17.57. In terms of profitability, DXCM's ROE is +0.24%, compared to SMLR's ROE of -0.21%. Regarding short-term risk, DXCM is less volatile compared to SMLR. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.
DXCM vs BFLY-WT Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, BFLY-WT has a market cap of 463.6M. Regarding current trading prices, DXCM is priced at $79.83, while BFLY-WT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas BFLY-WT's P/E ratio is N/A. In terms of profitability, DXCM's ROE is +0.24%, compared to BFLY-WT's ROE of -0.33%. Regarding short-term risk, DXCM is less volatile compared to BFLY-WT. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.
DXCM vs AXGN Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, AXGN has a market cap of 445.9M. Regarding current trading prices, DXCM is priced at $79.83, while AXGN trades at $9.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas AXGN's P/E ratio is -61.19. In terms of profitability, DXCM's ROE is +0.24%, compared to AXGN's ROE of -0.07%. Regarding short-term risk, DXCM is less volatile compared to AXGN. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.
DXCM vs BVS Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, BVS has a market cap of 432.7M. Regarding current trading prices, DXCM is priced at $79.83, while BVS trades at $6.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas BVS's P/E ratio is -13.58. In terms of profitability, DXCM's ROE is +0.24%, compared to BVS's ROE of -0.21%. Regarding short-term risk, DXCM is less volatile compared to BVS. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.
DXCM vs OFIX Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, OFIX has a market cap of 423.2M. Regarding current trading prices, DXCM is priced at $79.83, while OFIX trades at $10.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas OFIX's P/E ratio is -2.92. In terms of profitability, DXCM's ROE is +0.24%, compared to OFIX's ROE of -0.28%. Regarding short-term risk, DXCM is less volatile compared to OFIX. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.
DXCM vs SRDX Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, SRDX has a market cap of 414.7M. Regarding current trading prices, DXCM is priced at $79.83, while SRDX trades at $29.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas SRDX's P/E ratio is -20.71. In terms of profitability, DXCM's ROE is +0.24%, compared to SRDX's ROE of -0.17%. Regarding short-term risk, DXCM is more volatile compared to SRDX. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.
DXCM vs CTKB Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, CTKB has a market cap of 396.4M. Regarding current trading prices, DXCM is priced at $79.83, while CTKB trades at $3.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas CTKB's P/E ratio is -34.78. In terms of profitability, DXCM's ROE is +0.24%, compared to CTKB's ROE of -0.03%. Regarding short-term risk, DXCM is less volatile compared to CTKB. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.
DXCM vs SENS Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, SENS has a market cap of 377.1M. Regarding current trading prices, DXCM is priced at $79.83, while SENS trades at $0.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas SENS's P/E ratio is -4.55. In terms of profitability, DXCM's ROE is +0.24%, compared to SENS's ROE of -7.46%. Regarding short-term risk, DXCM is more volatile compared to SENS. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.
DXCM vs TMCI Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, TMCI has a market cap of 361.1M. Regarding current trading prices, DXCM is priced at $79.83, while TMCI trades at $5.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas TMCI's P/E ratio is -6.75. In terms of profitability, DXCM's ROE is +0.24%, compared to TMCI's ROE of -0.49%. Regarding short-term risk, DXCM is less volatile compared to TMCI. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.
DXCM vs PACB Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, PACB has a market cap of 355.6M. Regarding current trading prices, DXCM is priced at $79.83, while PACB trades at $1.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas PACB's P/E ratio is -0.43. In terms of profitability, DXCM's ROE is +0.24%, compared to PACB's ROE of -1.70%. Regarding short-term risk, DXCM is less volatile compared to PACB. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.
DXCM vs NPCE Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, NPCE has a market cap of 346.7M. Regarding current trading prices, DXCM is priced at $79.83, while NPCE trades at $10.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas NPCE's P/E ratio is -12.89. In terms of profitability, DXCM's ROE is +0.24%, compared to NPCE's ROE of -1.40%. Regarding short-term risk, DXCM is less volatile compared to NPCE. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.
DXCM vs VREX Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, VREX has a market cap of 324.9M. Regarding current trading prices, DXCM is priced at $79.83, while VREX trades at $7.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas VREX's P/E ratio is -7.60. In terms of profitability, DXCM's ROE is +0.24%, compared to VREX's ROE of -0.08%. Regarding short-term risk, DXCM is less volatile compared to VREX. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.
DXCM vs CLPT Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, CLPT has a market cap of 321.1M. Regarding current trading prices, DXCM is priced at $79.83, while CLPT trades at $11.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas CLPT's P/E ratio is -14.95. In terms of profitability, DXCM's ROE is +0.24%, compared to CLPT's ROE of -0.78%. Regarding short-term risk, DXCM is less volatile compared to CLPT. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.
DXCM vs NNOX Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, NNOX has a market cap of 315.6M. Regarding current trading prices, DXCM is priced at $79.83, while NNOX trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas NNOX's P/E ratio is -5.44. In terms of profitability, DXCM's ROE is +0.24%, compared to NNOX's ROE of -0.30%. Regarding short-term risk, DXCM is less volatile compared to NNOX. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.
DXCM vs OM Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, OM has a market cap of 306.2M. Regarding current trading prices, DXCM is priced at $79.83, while OM trades at $17.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas OM's P/E ratio is -0.60. In terms of profitability, DXCM's ROE is +0.24%, compared to OM's ROE of -1.45%. Regarding short-term risk, DXCM is less volatile compared to OM. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.
DXCM vs CATX Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, CATX has a market cap of 305.1M. Regarding current trading prices, DXCM is priced at $79.83, while CATX trades at $4.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas CATX's P/E ratio is -3.34. In terms of profitability, DXCM's ROE is +0.24%, compared to CATX's ROE of -0.27%. Regarding short-term risk, DXCM is less volatile compared to CATX. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.
DXCM vs SNWV Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, SNWV has a market cap of 286.3M. Regarding current trading prices, DXCM is priced at $79.83, while SNWV trades at $33.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas SNWV's P/E ratio is -5.37. In terms of profitability, DXCM's ROE is +0.24%, compared to SNWV's ROE of +1.00%. Regarding short-term risk, DXCM is less volatile compared to SNWV. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.
DXCM vs PTHL Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, PTHL has a market cap of 282.2M. Regarding current trading prices, DXCM is priced at $79.83, while PTHL trades at $19.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas PTHL's P/E ratio is -396.00. In terms of profitability, DXCM's ROE is +0.24%, compared to PTHL's ROE of -0.30%. Regarding short-term risk, DXCM is less volatile compared to PTHL. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.
DXCM vs VMD Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, VMD has a market cap of 263.6M. Regarding current trading prices, DXCM is priced at $79.83, while VMD trades at $6.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas VMD's P/E ratio is 22.23. In terms of profitability, DXCM's ROE is +0.24%, compared to VMD's ROE of +0.10%. Regarding short-term risk, DXCM is more volatile compared to VMD. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.
DXCM vs CERS Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, CERS has a market cap of 256.2M. Regarding current trading prices, DXCM is priced at $79.83, while CERS trades at $1.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas CERS's P/E ratio is -13.40. In terms of profitability, DXCM's ROE is +0.24%, compared to CERS's ROE of -0.35%. Regarding short-term risk, DXCM is less volatile compared to CERS. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.
DXCM vs QTRX Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, QTRX has a market cap of 244.8M. Regarding current trading prices, DXCM is priced at $79.83, while QTRX trades at $6.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas QTRX's P/E ratio is -5.08. In terms of profitability, DXCM's ROE is +0.24%, compared to QTRX's ROE of -0.15%. Regarding short-term risk, DXCM is less volatile compared to QTRX. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.
DXCM vs ZIMV Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, ZIMV has a market cap of 241.5M. Regarding current trading prices, DXCM is priced at $79.83, while ZIMV trades at $8.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas ZIMV's P/E ratio is -9.61. In terms of profitability, DXCM's ROE is +0.24%, compared to ZIMV's ROE of -0.04%. Regarding short-term risk, DXCM is less volatile compared to ZIMV. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.
DXCM vs MASS Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, MASS has a market cap of 238.5M. Regarding current trading prices, DXCM is priced at $79.83, while MASS trades at $6.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas MASS's P/E ratio is -3.00. In terms of profitability, DXCM's ROE is +0.24%, compared to MASS's ROE of -0.13%. Regarding short-term risk, DXCM is less volatile compared to MASS. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.
DXCM vs TCMD Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, TCMD has a market cap of 236.4M. Regarding current trading prices, DXCM is priced at $79.83, while TCMD trades at $10.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas TCMD's P/E ratio is 15.41. In terms of profitability, DXCM's ROE is +0.24%, compared to TCMD's ROE of +0.08%. Regarding short-term risk, DXCM is less volatile compared to TCMD. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.
DXCM vs MXCT Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, MXCT has a market cap of 230.2M. Regarding current trading prices, DXCM is priced at $79.83, while MXCT trades at $2.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas MXCT's P/E ratio is -5.41. In terms of profitability, DXCM's ROE is +0.24%, compared to MXCT's ROE of -0.20%. Regarding short-term risk, DXCM is less volatile compared to MXCT. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.
DXCM vs SGHT Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, SGHT has a market cap of 224.4M. Regarding current trading prices, DXCM is priced at $79.83, while SGHT trades at $4.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas SGHT's P/E ratio is -4.43. In terms of profitability, DXCM's ROE is +0.24%, compared to SGHT's ROE of -0.55%. Regarding short-term risk, DXCM is less volatile compared to SGHT. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.
DXCM vs NVRO Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, DXCM is priced at $79.83, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas NVRO's P/E ratio is -1.91. In terms of profitability, DXCM's ROE is +0.24%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, DXCM is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.
DXCM vs BWAY Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, BWAY has a market cap of 215.1M. Regarding current trading prices, DXCM is priced at $79.83, while BWAY trades at $11.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas BWAY's P/E ratio is 51.74. In terms of profitability, DXCM's ROE is +0.24%, compared to BWAY's ROE of +0.06%. Regarding short-term risk, DXCM is less volatile compared to BWAY. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.
DXCM vs EYES Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, EYES has a market cap of 210M. Regarding current trading prices, DXCM is priced at $79.83, while EYES trades at $4.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas EYES's P/E ratio is N/A. In terms of profitability, DXCM's ROE is +0.24%, compared to EYES's ROE of -0.26%. Regarding short-term risk, DXCM is less volatile compared to EYES. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.
DXCM vs BDMD Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, BDMD has a market cap of 204M. Regarding current trading prices, DXCM is priced at $79.83, while BDMD trades at $5.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas BDMD's P/E ratio is 11.65. In terms of profitability, DXCM's ROE is +0.24%, compared to BDMD's ROE of +0.12%. Regarding short-term risk, DXCM is less volatile compared to BDMD. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.
DXCM vs BSGM Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, BSGM has a market cap of 203.1M. Regarding current trading prices, DXCM is priced at $79.83, while BSGM trades at $7.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas BSGM's P/E ratio is -14.04. In terms of profitability, DXCM's ROE is +0.24%, compared to BSGM's ROE of +7.10%. Regarding short-term risk, DXCM is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.
DXCM vs TLSI Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, TLSI has a market cap of 200.2M. Regarding current trading prices, DXCM is priced at $79.83, while TLSI trades at $5.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas TLSI's P/E ratio is -4.81. In terms of profitability, DXCM's ROE is +0.24%, compared to TLSI's ROE of +1.04%. Regarding short-term risk, DXCM is less volatile compared to TLSI. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.
DXCM vs PROF Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, PROF has a market cap of 180.6M. Regarding current trading prices, DXCM is priced at $79.83, while PROF trades at $6.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas PROF's P/E ratio is -4.97. In terms of profitability, DXCM's ROE is +0.24%, compared to PROF's ROE of -0.70%. Regarding short-term risk, DXCM is less volatile compared to PROF. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.
DXCM vs INGN Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, INGN has a market cap of 179.3M. Regarding current trading prices, DXCM is priced at $79.83, while INGN trades at $6.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas INGN's P/E ratio is -5.80. In terms of profitability, DXCM's ROE is +0.24%, compared to INGN's ROE of -0.15%. Regarding short-term risk, DXCM is less volatile compared to INGN. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.
DXCM vs ELMD Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, ELMD has a market cap of 178.5M. Regarding current trading prices, DXCM is priced at $79.83, while ELMD trades at $21.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas ELMD's P/E ratio is 26.94. In terms of profitability, DXCM's ROE is +0.24%, compared to ELMD's ROE of +0.17%. Regarding short-term risk, DXCM is less volatile compared to ELMD. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.
DXCM vs ANIK Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, ANIK has a market cap of 156.6M. Regarding current trading prices, DXCM is priced at $79.83, while ANIK trades at $10.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas ANIK's P/E ratio is -14.56. In terms of profitability, DXCM's ROE is +0.24%, compared to ANIK's ROE of -0.33%. Regarding short-term risk, DXCM is less volatile compared to ANIK. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.
DXCM vs CVRX Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, CVRX has a market cap of 149.1M. Regarding current trading prices, DXCM is priced at $79.83, while CVRX trades at $5.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas CVRX's P/E ratio is -2.67. In terms of profitability, DXCM's ROE is +0.24%, compared to CVRX's ROE of -0.79%. Regarding short-term risk, DXCM is less volatile compared to CVRX. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.
DXCM vs LNSR Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, LNSR has a market cap of 145.7M. Regarding current trading prices, DXCM is priced at $79.83, while LNSR trades at $12.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas LNSR's P/E ratio is -2.52. In terms of profitability, DXCM's ROE is +0.24%, compared to LNSR's ROE of -5.28%. Regarding short-term risk, DXCM is less volatile compared to LNSR. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.
DXCM vs AVR Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, AVR has a market cap of 141.7M. Regarding current trading prices, DXCM is priced at $79.83, while AVR trades at $3.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas AVR's P/E ratio is -1.10. In terms of profitability, DXCM's ROE is +0.24%, compared to AVR's ROE of -2.92%. Regarding short-term risk, DXCM is less volatile compared to AVR. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.
DXCM vs RPID Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, RPID has a market cap of 138.9M. Regarding current trading prices, DXCM is priced at $79.83, while RPID trades at $3.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas RPID's P/E ratio is -3.08. In terms of profitability, DXCM's ROE is +0.24%, compared to RPID's ROE of -0.56%. Regarding short-term risk, DXCM is less volatile compared to RPID. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.
DXCM vs RCEL Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, RCEL has a market cap of 135.9M. Regarding current trading prices, DXCM is priced at $79.83, while RCEL trades at $5.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas RCEL's P/E ratio is -2.35. In terms of profitability, DXCM's ROE is +0.24%, compared to RCEL's ROE of -3.38%. Regarding short-term risk, DXCM is less volatile compared to RCEL. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.
DXCM vs LUCD Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, LUCD has a market cap of 128.2M. Regarding current trading prices, DXCM is priced at $79.83, while LUCD trades at $1.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas LUCD's P/E ratio is -1.01. In terms of profitability, DXCM's ROE is +0.24%, compared to LUCD's ROE of +26.96%. Regarding short-term risk, DXCM is less volatile compared to LUCD. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.
DXCM vs OWLT Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, OWLT has a market cap of 123.3M. Regarding current trading prices, DXCM is priced at $79.83, while OWLT trades at $7.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas OWLT's P/E ratio is -4.63. In terms of profitability, DXCM's ROE is +0.24%, compared to OWLT's ROE of +1.25%. Regarding short-term risk, DXCM is less volatile compared to OWLT. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.
DXCM vs LUNG Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, LUNG has a market cap of 103.5M. Regarding current trading prices, DXCM is priced at $79.83, while LUNG trades at $2.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas LUNG's P/E ratio is -1.78. In terms of profitability, DXCM's ROE is +0.24%, compared to LUNG's ROE of -0.64%. Regarding short-term risk, DXCM is less volatile compared to LUNG. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.
DXCM vs MGRM Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, MGRM has a market cap of 100.5M. Regarding current trading prices, DXCM is priced at $79.83, while MGRM trades at $2.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas MGRM's P/E ratio is -5.63. In terms of profitability, DXCM's ROE is +0.24%, compared to MGRM's ROE of -1.26%. Regarding short-term risk, DXCM is less volatile compared to MGRM. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.
DXCM vs ICAD Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, ICAD has a market cap of 100.3M. Regarding current trading prices, DXCM is priced at $79.83, while ICAD trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas ICAD's P/E ratio is -19.21. In terms of profitability, DXCM's ROE is +0.24%, compared to ICAD's ROE of -0.17%. Regarding short-term risk, DXCM is less volatile compared to ICAD. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.
DXCM vs HJLI Comparison
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 31.3B. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, DXCM is priced at $79.83, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 60.02, whereas HJLI's P/E ratio is N/A. In terms of profitability, DXCM's ROE is +0.24%, compared to HJLI's ROE of -0.51%. Regarding short-term risk, DXCM is less volatile compared to HJLI. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.